The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design?

Drug Discovery Today

Volumn 14, Issue 21-22, 2009, Pages 1011-1020

  Ritchie, Timothy J ^a   Macdonald, Simon J F ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUND; CYTOCHROME P450; DRUG; POTASSIUM CHANNEL HERG; SERUM ALBUMIN;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MARKETING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IN VITRO STUDY; INHIBITION KINETICS; LIPOPHILICITY; MOLECULAR WEIGHT; REVIEW; THERMODYNAMICS;

CARBONIC ANHYDRASE INHIBITORS; CYTOCHROME P-450 CYP3A; DRUG DESIGN; ENZYME INHIBITORS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; HYDROCARBONS, AROMATIC; INTESTINAL ABSORPTION; LIPIDS; LUMINESCENCE; POTASSIUM CHANNEL BLOCKERS; PROTEIN BINDING; SERUM ALBUMIN; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350409235     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.014     Document Type: Review

References (23)

1. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
2. Leeson P.D., and Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6 (2007) 881-890
3. Muresan S., and Sadowski J. Properties guiding drug- and lead-likeness. Methods and Principles in Medicinal Chemistry (2008), Wiley InterScience pp. 439-461
4. Spotfire DXP 2.0 or DecisionSite 8.2.1
5. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
6. Hann M.M., et al. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41 (2001) 856-864
7. Wenlock M.C., et al. A comparison of physicochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46 (2003) 1250-1256
8. Palm K., et al. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997) 568-571
9. Veber D.F., et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 (2002) 2615-2623
10. Hughes J.D., et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18 (2008) 4872-4875
11. Ran Y., and Yalkowsky S.H. Prediction of drug solubility by the general solubility equation (GSE). J. Chem. Inf. Comput. Sci. 41 (2001) 354-357
12. Lamanna C., et al. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process. J. Med. Chem. 51 (2008) 2891-2897
13. Valko K., et al. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol-water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 92 (2003) 2236-2248
14. Sudlow G., et al. Characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11 (1975) 824-832
15. Trainor G.L. The importance of plasma protein binding in drug discovery. EODC 2 (2007) 51-64
16. Lewis D.F.V., and Dickins M. Substrate SAR in human p450s. Drug Discov. Today 7 (2002) 918-925
17. Blagg J. Structure activity relationships for in vitro and in vivo toxicity. Annu. Rep. Med. Chem. 41 (2006) 353-358
18. Hop C.E.C.A., et al. Importance of early assessment of bioactivation in drug discovery. Annu. Rep. Med. Chem. 41 (2006) 369-381
19. Jamieson C., et al. Medicinal chemistry of hERG optimizations: highlights and hang-ups. J. Med. Chem. 49 (2006) 5029-5046
20. Wood A., and Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43 (2005) 239-271
21. Santella J.B., et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis. Bioorg. Med. Chem. Lett. 18 (2008) 576-585
22. Gardner D.S., et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists. Bioorg. Med. Chem. Lett. 18 (2008) 586-595
23. Leeson P.D., and Davis A.M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 47 (2004) 6338-6348